Hepatitis D Genome First Virus Loaded Into Quantum Computer

Scientists in China have successfully loaded the genome of the hepatitis D virus onto a quantum computer, marking the first time a pathogenic virus’s complete genetic sequence has been processed using quantum hardware.

The breakthrough was achieved by researchers at the University of Science and Technology of China, who encoded the 1.7-kilobase circular RNA genome of hepatitis D virus into a superconducting quantum processor. The virus, known for causing the most severe form of viral hepatitis, relies on hepatitis B virus for replication and infects nearly 50 million people worldwide.

Using a 66-qubit programmable superconducting chip named Zuchongzhi 2.1, the team mapped the viral genome’s nucleotide sequence onto quantum states, enabling the simulation of its secondary RNA structure and potential interactions with host factors. This approach allows for the modeling of molecular behaviors that are computationally intractable for classical systems due to the virus’s compact yet highly folded RNA architecture.

The researchers emphasized that the achievement represents a proof-of-concept for applying quantum computing to virology, particularly for pathogens with small, structured genomes that pose challenges for traditional computational methods. They noted that accurate simulation of RNA folding and protein-binding sites could accelerate the identification of therapeutic targets, especially given the limited treatment options currently available for hepatitis D.

While the study does not claim to have discovered new drugs or mechanisms, it establishes a foundation for using quantum processors to explore viral evolution, drug resistance, and host-pathogen interactions at a level of detail beyond classical simulation capabilities. The team plans to extend the work to other RNA viruses with public health significance.

The results were published in the peer-reviewed journal Chinese Physics Letters and have been cited in subsequent discussions on quantum applications in biomedicine, though no follow-up experimental validations or clinical trials have been announced as of this reporting.